# $biovcn

BioVaxys announces positive clinical study results for its MVP-S trial in ovarian cancer, with a patient maintaining complete response for three years. The company is also highlighting its platform technology and strategic partnerships in both human and animal health.

### About $biovcn
This refers to BioVaxys Technology Corp., a company involved in biotechnology and drug development, particularly in the areas of cancer immunotherapy and animal health.  

### Insights
- $biovcn mentions hit [--] which is 126% higher than it's daily average.

### Top $biovcn Social Posts
Top posts by engagements in the last [--] hours

*Showing a maximum of [--] top social posts without a LunarCrush subscription.*

"$BVAXF $BIOV.CN BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S $TSLA $AAPL $NVDA $BTC $SPY $AMD $AMZN $MSFT $ETH $QQQ $GOOGL $META $NFLX $SOL $DOGE $PLTR $ASST $AVGO https://finance.yahoo.com/news/biovaxys-reports-positive-clinical-study-130000795.html $BVAXF $BIOV.CN BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer. 🌏Study subject Remains in Complete Response for [--] Years https://t.co/IkHpctYHNl"  
[X Link](https://x.com/Stockmafia729/status/2013639444713075137) [@Stockmafia729](/creator/x/Stockmafia729) 2026-01-20T15:47Z [--] followers, [---] engagements


"$BVAXF $BIOV.CN BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO with Keytruda Patients with Recurrent Epithelial Ovarian Cancer. $AI $AIRE $ASST $AVNT $BBAI $BEEM $CHYM $CLSK $COIN $DORA $LMND $MIST $NBIS $NVTS $OPEN $OSCR $OVPP $RBRK $ROOT $UB $PFE $XBI $BVAXF $BIOV.CN BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer. 🌏Study subject Remains in Complete Response for [--] Years https://t.co/IkHpctYHNl $BVAXF $BIOV.CN"  
[X Link](https://x.com/jasminetradesX/status/2013610330350293342) [@jasminetradesX](/creator/x/jasminetradesX) 2026-01-20T13:51Z [---] followers, [---] engagements


"$BVAXF $BIOV.CN BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO with Keytruda Patients with Recurrent Epithelial Ovarian Cancer. $AI $AIRE $ASST $AVNT $BBAI $BEEM $CHYM $CLSK $COIN $DORA $LMND $MIST $NBIS $NVTS $OPEN $OSCR $OVPP $RBRK $ROOT $UB $PFE $JNJ $BVAXF $BIOV.CN BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer. 🌏Study subject Remains in Complete Response for [--] Years https://t.co/IkHpctYHNl $BVAXF $BIOV.CN"  
[X Link](https://x.com/bigbluefinances/status/2013609997838516374) [@bigbluefinances](/creator/x/bigbluefinances) 2026-01-20T13:50Z [--] followers, [---] engagements


"$BVAXF $BIOV.CN BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO with Keytruda Patients with Recurrent Epithelial Ovarian Cancer. $AI $AIRE $ASST $AVNT $BBAI $BEEM $CHYM $CLSK $COIN $DORA $LMND $MIST $NBIS $NVTS $OPEN $OSCR $OVPP $RBRK $ROOT $UB $PFE $SLV $BVAXF $BIOV.CN BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer. 🌏Study subject Remains in Complete Response for [--] Years https://t.co/IkHpctYHNl $BVAXF $BIOV.CN"  
[X Link](https://x.com/stocksstalker01/status/2013609869061038120) [@stocksstalker01](/creator/x/stocksstalker01) 2026-01-20T13:49Z [--] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing